Source: Annual Congress 2009 - Treatment of lung cancer
Disease area: Thoracic oncology

Abstract

Introduction: In developed countries lung cancer is the most important cause of death. About 1/3 of patients with NSCLC present themselves in the early stage, with the possibility of curative surgery, however the risk of recurrence and death is substantial. Many studies have been made to evaluate the use of adjuvant chemotherapy (QT) in stage IB.
Objectives: Assess results of the use of adjuvant QT in stage IB and its effects on the survival of patients with NSCLC, treated in the HUC.
Methods: Retrospective study, including 840 new patients with lung cancer, of the Pneumology Department, in the period 2000-2007.
Individuals with NSCLC stage IB were distributed by gender, age, smoking habits, histological type and physiological state.
In patients submitted to surgery was performed a comparative analysis of survival between two groups; treated(A) or not (B) with adjuvant QT.
Results: Total 840 patients, 55 stage IB NSCLC; 82% men; average age 66 years; 67% smokers or former smokers; performance status 0(9), 1(42) and 2(2). Epidermoid (19 cases) and adenocarcinoma (27 cases). Surgery with curative intent was performed in 48 patients, divided in groups A (27) and B (21). The survival average was: groups A, 3.3 years (sd 1.86) and B, 3.48 years (sd 2.85). The survival probability for: 2 years, A-70% and B-50%; 5 years, A-15% and B-20%; and 7 years, A-7% and B-20%.
Conclusions: In our patients, the adjuvant QT has some benefit in a short-term survival probability, but in a long term (5-7 years) there is a low benefit or even disadvantage in its use.
Future investigations, based on biological markers are important, in order to obtain more reliable conclusions on this matter.

Rating:

Share or cite this content

Citations should be made in the following way:
S. Andre, M. J. Guimaraes, C. Valente, A. Pego, A. Sousa, M. Loureiro, M. Baganha (Coimbra, Portugal). Adjuvant chemotherapy in stage Ib of non-small cell lung cancer (NSCLC)-experience of a pneumology department. Eur Respir J 2009; 34: Suppl. 53, 2654

Member's Comments

No comment yet.

Related content which might interest you: Adjuvant chemotherapy in stage IB nonsmall cell lung cancer Source: Breathe 2009; 5: 361 Year: 2009 Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009 Radiotherapy with curative intent for stage I and II non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Radiotherapy for stage III non-small cell lung cancer (NSCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Interdisciplinary multimodality management of stage III nonsmall cell lung cancer Source: Eur Respir Rev, 28 (152) 190024; 10.1183/16000617.0024-2019 Year: 2019 Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Chemotherapy in advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 271–283 Year: 2009 Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Radical radiotherapy in medically inoperable early stage non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 Use of adjuvants to chemotherapy in stage IV nonsmall cell lung carcinoma (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Radiotherapy in the treatment of nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 207–243 Year: 2009 Treatment of advanced non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Combined radiotherapy for nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 Locally advanced inoperable non-small cell lung cancer (NSCLC) treated by weekly paclitaxel/carboplatin chemotherapy with concomitant radiotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 433s Year: 2007 Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 The role of palliative radiotherapy in locally advanced non small cell lung cancer Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007